{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:44Z","timestamp":1789142804989,"version":"build-2803163510"},"reference-count":24,"publisher":"Hogrefe Publishing Group","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,11]]},"abstract":" Zusammenfassung. Eine Tuberkulose manifestiert sich normalerweise pulmonal, kann jedoch in jedes Organ disseminieren. Die h\u00e4ufigsten Manifestationsorte einer extrapulmonalen Tuberkulose sind Lymphknoten, die Pleura und die Knochen. Die Wahrscheinlichkeit der Dissemination einer Tuberkulose erh\u00f6ht sich bei einem immunsupprimierten Patienten, z.B. durch HIV oder einen TNF-alpha-Inhibitor. Die Diagnose einer extrapulmonalen Tuberkulose ist schwierig. Oft ist eine invasive Herangehensweise zur Probengewinnung n\u00f6tig, um den Tuberkuloseerreger M. tuberculosis durch Mikroskopie, Kultur, Mikrobiologie (z.B. Xpert\u00ae MTB\/RIF) oder Histologie nachzuweisen. Die Behandlung einer extrapulmonalen Tuberkulose folgt den Richtlinien der Therapie einer pulmonalen Tuberkulose mit einer zweimonatigen antibiotischen Vierfachtherapie (Rifampicin, Isoniazid, Ethambuthol und Pyrazinamid), gefolgt von einer viermonatigen antibiotischen Zweifachtherapie (Rifampicin und Isoniazid). Die Dauer der antibiotischen Behandlung ist bei einer tuberkul\u00f6sen Meningitis auf ein Jahr und bei einer skelettalen Dissemination auf sechs bis neun Monate verl\u00e4ngert. Kortikosteroide sind bei einer tuberkul\u00f6sen Meningoenzephalitis und Perimyokarditis empfohlen. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003370","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T07:30:21Z","timestamp":1574839821000},"page":"1019-1026","source":"Crossref","is-referenced-by-count":4,"title":["CME: Extrapulmonale Tuberkulose"],"prefix":"10.1024","volume":"108","author":[{"given":"Armon","family":"Arpagaus","sequence":"first","affiliation":[{"name":"St. Claraspital, Basel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Weisser","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Infektiologie & Spitalhygiene, Universit\u00e4tsspital Basel"},{"name":"Schweizerisches Tropen- und Public Health-Institut, Universit\u00e4t Basel"},{"name":"Universit\u00e4t Basel"},{"name":"Ifakara Health Institute, Ifakara, United Republic of Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"101","reference":[{"key":"c1","unstructured":"WHO, Anderson L, Baddeley A, Dias HM, Floyd K, Baena IG: Global Tuberculosis Report 2018. Geneva; WHO: 2018."},{"key":"c2","unstructured":"Otto D, Schoch JB, Berger C, et al. Tuberkulose in der Schweiz \u2013 Leitfaden f\u00fcr Fachpersonen des Gesundheitswesens. Bern; Bundesamt f\u00fcr Gesundheit: 2019."},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1086\/605559"},{"key":"c4","first-page":"18","volume":"42","author":"Houston A","year":"2014","journal-title":"Medicine (United Kingdom)"},{"key":"c5","doi-asserted-by":"publisher","DOI":"10.1111\/2049-632X.12108"},{"key":"c6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01481.x"},{"key":"c7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"c8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"c9","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.876"},{"key":"c10","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12900"},{"key":"c11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.120"},{"key":"c12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507062"},{"key":"c13","first-page":"Cd000526","volume":"9","author":"Wiysonge CS","year":"2017","journal-title":"The Cochrane Database Syst Rev"},{"key":"c14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70163-8"},{"key":"c15","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0561"},{"key":"c16","doi-asserted-by":"crossref","unstructured":"Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N: Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1: Cd009593.","DOI":"10.1002\/14651858.CD009593.pub3"},{"key":"c17","unstructured":"WHO; Sch\u00fcnemann H, et al. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017. Geneva; World Health Organization: 2017."},{"key":"c18","author":"WHO","year":"2019","journal-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment"},{"key":"c19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"c20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040573"},{"key":"c21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407380"},{"key":"c22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.02.002"},{"key":"c23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2009.11.030"},{"key":"c24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz154"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T05:39:57Z","timestamp":1615959597000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1024\/1661-8157\/a003370"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003370","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}